Gelonghui, December 14|Libretech (688056.SH) recently stated during a survey from institutional investors that the company is mainly managed according to product division divisions. Currently, it is mainly divided into sample pre-processing analysis instrument division, laboratory equipment division, solution division, consumables and customer service division, medical and pharmaceutical division, mass spectrometry division, and automated intelligent analysis and testing division. The company will evaluate the actual needs of each division to ensure product development speed and sales performance. Before a product development project is established, such as the current research project, inductively coupled plasma quadrupole-time-of-flight mass spectrometer (ICP-Q-TOF-MS), full-spectrum direct-reading inductively coupled plasma spectrometer (full-spectrum direct reading ICP spectrometer), gas chromatography-single quadrupole mass spectrometer (GC-MS), etc., will comprehensively consider factors such as product application areas and market space based on the company's overall product line situation. At the same time, the company will also carry out R&D and sales layout in a timely manner according to changes in industry application needs. Compared with traditional industries such as disease control, environmental protection, and food safety, the company has invested more energy in the semiconductor, medical, pharmaceutical, and nuclide industries in recent years.